Lucid Diagnostics (LUCD) Common Equity (2021 - 2025)
Lucid Diagnostics (LUCD) has disclosed Common Equity for 5 consecutive years, with $25.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Common Equity rose 307.62% year-over-year to $25.8 million, compared with a TTM value of $25.8 million through Sep 2025, up 307.62%, and an annual FY2024 reading of $5.4 million, up 333.28% over the prior year.
- Common Equity was $25.8 million for Q3 2025 at Lucid Diagnostics, up from $7.9 million in the prior quarter.
- Across five years, Common Equity topped out at $54.7 million in Q4 2021 and bottomed at -$24.1 million in Q3 2021.
- Average Common Equity over 5 years is $12.4 million, with a median of $11.9 million recorded in 2024.
- The sharpest move saw Common Equity surged 384.07% in 2022, then plummeted 145.21% in 2025.
- Year by year, Common Equity stood at $54.7 million in 2021, then crashed by 57.9% to $23.0 million in 2022, then plummeted by 110.03% to -$2.3 million in 2023, then soared by 333.28% to $5.4 million in 2024, then skyrocketed by 379.22% to $25.8 million in 2025.
- Business Quant data shows Common Equity for LUCD at $25.8 million in Q3 2025, $7.9 million in Q2 2025, and -$5.4 million in Q1 2025.